Vanquish Oncology, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2011-01-01
- Employees
- 1
- Market Cap
- -
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Vanquish Oncology, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03332355
- Locations
- 🇺🇸
Regions Hospital, Saint Paul, Minnesota, United States
🇺🇸Johns Hopkins Cancer Center, Baltimore, Maryland, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-02-04
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- Vanquish Oncology, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02355535
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Regions Hospital, Saint Paul, Minnesota, United States
© Copyright 2024. All Rights Reserved by MedPath